Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
The following discussion and analysis of our financial condition and results of operations should be read together with the unaudited condensed consolidated financial statements and related notes included in Item 1 of Part I of this Quarterly Report on Form 10-Q and with the audited financial statements and the related notes included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, as filed with the SEC on February 27, 2023.
PITTSBURGH, April 18, 2023 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc. (“Jeune”), a wholly-owned subsidiary of Krystal Biotech, Inc. (“Krystal”) (NASDAQ: KRYS), today announced treatment of the first subject in the Phase 1, Cohort 3 study of KB301 for the improvement of lateral canthal lines at rest. Jeune’s lead product candidate, KB301, delivers the human COL3A1 gene to targeted skin cells that in turn produce natural type 3 collagen.
PITTSBURGH, April 18, 2023 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc. (“Jeune”), a wholly-owned subsidiary of Krystal Biotech, Inc. (“Krystal”) (NASDAQ: KRYS), today announced treatment of the first subject in the Phase 1, Cohort 3 study of KB301 for the improvement of lateral canthal lines at rest. Jeune’s lead product candidate, KB301, delivers the human COL3A1 gene to targeted skin cells that in turn produce natural type 3 collagen.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
